AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,327.50GBp
24 Oct 2014
Price Change (% chg)

-7.00p (-0.16%)
Prev Close
4,334.50p
Open
4,280.00p
Day's High
4,334.50p
Day's Low
4,241.50p
Volume
2,021,550
Avg. Vol
2,656,120
52-wk High
4,946.41p
52-wk Low
3,194.50p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.40
Market Cap (Mil.): £54,441.48
Shares Outstanding (Mil.): 1,262.75
Dividend: 53.10
Yield (%): 3.93

Financials

  AZN.L Industry Sector
P/E (TTM): 43.21 33.21 34.06
EPS (TTM): 1.00 -- --
ROI: 5.03 18.18 17.45
ROE: 8.94 18.85 18.26
Search Stocks

UPDATE 2-Bristol-Myers tops 3rd-qtr estimates as sales of top drugs sizzle

(Adds analyst comment, details on Opdivo cancer drug, shares)

24 Oct 2014

AstraZeneca cancer drug pipeline gets boost from European green light

LONDON - AstraZeneca's cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

24 Oct 2014

UPDATE 1-AstraZeneca cancer drug pipeline gets boost from European green light

* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)

24 Oct 2014

AstraZeneca ovarian cancer drug wins European green light

LONDON, Oct 24 - AstraZeneca's cancer drug pipeline received a boost on Friday as European regulators recommended approval of an experimental medicine against ovarian cancer.

24 Oct 2014

Pfizer's $11 billion buyback plan deflates AstraZeneca bid hopes

LONDON/NEW YORK - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.

24 Oct 2014

Banks could miss out on $135 million fees as Abbvie drops Shire deal

LONDON - A decision by U.S. drugmaker AbbVie to scrap its plans to buy Dublin-based Shire could mean that bankers miss out on up to $135 million in fees linked to the deal.

16 Oct 2014

Novartis psoriasis drug benefits outweighs risk-FDA staff

- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

UPDATE 1-Novartis psoriasis drug benefits outweighs risk-FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

AstraZeneca looks to EU decision for next cancer drug boost

LONDON - AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

14 Oct 2014

AstraZeneca looks to EU decision for next cancer drug boost

LONDON - AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

14 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks